Alvotech (ALVO) Stock Price & Analysis
Alvotech (ALVO) is trading at USD 4.65, down 2.92% today, as of October 23, 2026 at 15:44 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ALVO last closed at USD 4.65; today's session has ranged USD 4.63–4.78 on volume of 323,653 shares. Market capitalization is —, with a 52-week range of USD 2.94–8.5 (NGM). Source: Nexqual, retrieved October 23, 2026 at 15:45 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALVO.md
Key facts (ALVO)
- 1 of 80 tracked superinvestors hold ALVO (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y -42.9% vs S&P 500 +14.7%; 5Y -52.1% vs S&P 500 +77.4%.
- Next earnings: 2026-11-11, EPS estimate USD -0.05, revenue estimate $138M.
Superinvestors (SEC 13F-HR, Q2 2026) (ALVO)
1 of 80 tracked investors hold ALVO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Howard Marks | Oaktree Capital | 0.04% | $1.4M | Reduced -0.1% |
Analysts (ALVO)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Barclays | Upgrade | Underweight → Overweight | $4 → $8 |
| 2026-08-24 | B of A Securities | Initiated | Buy | $7 |
| 2026-08-14 | Evercore ISI Group | Initiated | Outperform |
Total return (dividends reinvested) (ALVO)
| 1Y (from 2025-10-23) | 5Y (from 2022-06-13) | |
|---|---|---|
| Total return | -42.9% | -52.1% |
| S&P 500 (SPY) | +14.7% | +77.4% |
| Per year | -43.0% | -15.5% |
| Volatility (annualized) | 81.3% | 59.8% |
| Max drawdown | -64.3% (Oct 2025→Jun 2026) | -80.9% (Feb 2024→Jul 2026) |
ALVO suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Stada Arzneimittel | “Alvotech has entered into a number of license and supply agreements with STADA pursuant to which we granted STADA licenses on an exclusive or semi exclusive basis (depending on the market) to import, commercialize and market certain products containing AVT02, AVT03, AVT04 and AVT06 in the European Union and certain other countries.” |
| Supplier | The Nasdaq Stock Market | “As long as we rely on the foreign private issuer exemption to certain of Nasdaq's corporate governance standards, a majority of the directors on our board of directors are not required to be independent directors, our remuneration committee is not required to be comprised entirely of independent directors, and we will not be required to have a nominating and corporate governance committee.” |
| Partner | Fuji Pharma | “Our ability to continue to generate revenue and achieve sustainable profitability will continue to depend on our ability and that of our strategic collaboration partners, to successfully commercialize our first approved biosimilars, AVT02 and AVT04 in the United States, European Economic Area ("EEA"), Canada, UK and Japan (AVT04 only), and our newly approved biosimilars AVT03, AVT05, and AVT06 in the EEA, UK and J…” |
| Partner | Teva Pharmaceuticals International | “Our partners include Teva (U.S.), STADA (EU), Fuji Pharma Co., Ltd (Japan), JAMP Pharma (Canada), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand) and Dr. Reddy's (Global) among many others.” |
| Partner | Laboratories | “Alvotech and our partner Dr. Reddy's Laboratories are involved in legal proceedings adverse to Amgen that may have an impact on our AVT 03 product in the United States.” |
| Partner | Alvogen | “As of the date hereof, our two largest shareholders, Alvogen Lux Holdings S.à r.l. ("Alvogen") and Aztiq Pharma Partners SARL ("Aztiq"), own approximately 62.2% of our ordinary shares.” |
| Partner | Kashiv Biosciences | “In 2023, we announced an agreement with Kashiv Biosciences LLC ("Kashiv") to in-license AVT23.” |
| Partner | JAMP Pharma | “Our partners include Teva (U.S.), STADA (EU), Fuji Pharma Co., Ltd (Japan), JAMP Pharma (Canada), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand) and Dr. Reddy's (Global) among many others.” |
| Competitor | AbbVie (ABBV) | “For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz; in the market for AVT04, our biosimilar to Stelara (ustekinumab), we compete against Janssen (the originator), Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bio…” |
| Competitor | Pfizer (PFE) | “For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz; in the market for AVT04, our biosimilar to Stelara (ustekinumab), we compete against Janssen (the originator), Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bio…” |
| Competitor | Johnson & Johnson (JNJ) | “In addition to Johnson & Johnson's (the originator's) reference product, we can face competition from other approved biosimilars for Stelara (ustekinumab) in the U.S. and EEA, including biosimilars from Intas, Amgen, Biocon, Celltrion, Formycon, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Accord and Bio-Thera.” |
Quoted from the company's 20-F filed Mar 31, 2026.
ALVO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.05 | $0.02 | -362.7% | $138.1M | 2 |
| Next quarter (ends Dec 2026) | $0.21 | $0.08 | +164.1% | $308.6M | 2 |
| Current fiscal year (ends Dec 2026) | $-0.03 | $0.03 | -205.5% | $652.7M | 4 |
| Next fiscal year (ends Dec 2027) | $0.23 | $0.23 | -2.0% | $785.9M | 5 |
Key Statistics (as of October 23, 2026 at 15:45 UTC)
| Price | USD 4.65 |
|---|---|
| Change | ▼ 2.92% (down) |
| Previous Close | USD 4.65 |
| Open | USD 4.65 |
| Day Range | USD 4.63 – 4.78 |
| 52-Week Range | USD 2.94 – 8.5 |
| Volume | 323,653 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (ALVO)
Nexqual's technical model rates ALVO "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 15:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.54 (neutral) |
| vs SMA50 | Below (USD 5.24) |
| MACD | -0.13 (negative) |
Earnings (ALVO)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $138.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.08 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD 0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.03 ▼ miss |
Source: Nexqual, October 23, 2026 at 15:45 UTC.
Financials & Fundamentals (ALVO)
| Total Revenue | $494.61M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -38.90% |
| Gross Margin | +60.66% |
| Operating Margin | -11.05% |
| Profit Margin | -36.31% |
| Current Ratio | 1.65 |
| Total Cash | $142.75M |
| Total Debt | $1.45B |
Source: Nexqual, October 23, 2026 at 15:45 UTC.
Ownership (ALVO)
| Insider Ownership | +59.68% |
|---|---|
| Institutional Ownership | +12.82% |
| Shares Outstanding | 356.82M |
| Float | 140.79M |
| Short % of Float | +3.95% |
Source: Nexqual, October 23, 2026 at 15:45 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHC | Sotera Health Company | USD 18.05 | ▼ 0.47% |
| ROIV | Roivant Sciences Ltd. | USD 36.95 | ▼ 1.34% |
| PROK | ProKidney Corp. | USD 1.39 | ▼ 2.8% |
| EVO | Evotec SE | USD 1.52 | ▼ 1.62% |
| ALHC | Alignment Healthcare, Inc. | USD 8.02 | ▼ 4.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:45 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt